Corrado Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Corrado Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-450	Closed	-$5.41K	–	296
2022 Q4	$5.41K	Buy	+450	New	+$3.5K	﹤0.01%	262

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SIGI

Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Corrado Advisors's ORMP Position: Q1 2023 in Review

Corrado Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 450 shares — an estimated $5.41K sold.

Corrado Advisors first reported a position in ORMP in Q4 2022 and held it in 1 quarter. The position peaked at $5.41K in Q4 2022. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

Corrado Advisors reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Corrado Advisors sold 450 Oramed Pharmaceuticals shares in Q1 2023, an estimated $5.41K.
Corrado Advisors first reported a position in Oramed Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Corrado Advisors's Oramed Pharmaceuticals position peaked at $5.41K in Q4 2022.
61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on Corrado Advisors's 13F filing for Q1 2023, filed 3 May 2023.